An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome

PHASE2SuspendedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 28, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Fragile X SyndromeBehaviorCognitive Dysfunction
Interventions
DRUG

Psilocybin, 1.5 mg

Blister packs will contain five capsules of the study drug, Psilocybin 1.5mg. Subjects will be given blister packs with weekly doses at each visit including baseline (day 1), day 8, day 15, day 21, and day 28. Weekly blister packs will contain five doses (1-2 extra capsules depending on the week) to accommodate for flexibility in scheduling. Unused and open packages will be returned to study staff at each visit after baseline.

Trial Locations (1)

N6B 3L1

KGK Science Inc., London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

KGK Science Inc.

INDUSTRY

lead

Nova Mentis Life Science Corp

INDUSTRY